Published: Tue, August 29, 2017
Money | By Oscar Reynolds

Gilead Buys Kite Pharma, Founded by Israelis, for $11.9 Billion

Gilead Buys Kite Pharma, Founded by Israelis, for $11.9 Billion

The rating was upgraded by Societe Generale on Tuesday, January 10 to "Buy". The firm earned "Overweight" rating on Thursday, November 5 by Piper Jaffray. The firm earned "Buy" rating on Monday, September 12 by Berenberg.

Shares of Kite reached a new all-time high on Monday, and the company's shares have already traded hands more than eight times its average volume. The hedge fund held 225,000 shares of the health care company at the end of 2016Q4, valued at $16.11 million, down from 275,000 at the end of the previous reported quarter. Gilead Sciences Inc now has $98.41B valuation. About 1.10M shares traded. Kite Pharma Inc (NASDAQ:KITE) has risen 55.47% since August 28, 2016 and is uptrending.

The Bank of Nova Scotia is an global bank and a financial services well-known provider in North America, Latin America, the Caribbean and Central America, and Asia-Pacific. The company has market cap of $10.19 billion. It has a 8.55 P/E ratio. When considering if perhaps the stock is under or overvalued, the average price target is $103.00 which is -26.0% under where the stock closed last Friday. (NYSE:SBH) has declined 34.87% since August 28, 2016 and is downtrending. It has underperformed by 0.18% the S&P500.

In other Gilead Sciences news, EVP Gregg H. Alton sold 40,000 shares of Gilead Sciences stock in a transaction that occurred on Friday, July 21st. (NASDAQ:GILD) for 2,989 shares. Cogan John Francis sold $668,667 worth of stock or 9,943 shares.

Investors sentiment increased to 0.93 in Q4 2016. Its up 0.21, from 0.7 in 2016Q3. (GILD) for $180 per share in cash. ANTIPODES PARTNERS Ltd raised its position in shares of Gilead Sciences by 23.4% in the first quarter. 950.84 million shares or 0.69% more from 944.29 million shares in 2016Q3 were reported. The stock rose 0.73% or $1.24 reaching $170.98. (NASDAQ:GILD). Macguire Cheswick & Tuttle Inv Counsel Lc holds 128,351 shares or 1.89% of its portfolio. Wells Fargo Mn reported 11.31 million shares stake. (NASDAQ:GILD). United Kingdom-based Old Mutual (Uk) has invested 0.64% in Gilead Sciences, Inc. More interesting news about Gilead Sciences, Inc.

"We are excited that Gilead, one of the most innovative companies in the industry, recognized this value and shares our passion for developing cutting-edge and potentially curative therapies for patients", Belldegrun added. Telemus Capital Limited Liability Company invested in 0.42% or 43,356 shares. The Ontario - Canada-based Toronto Dominion Savings Bank has invested 0.06% in Gilead Sciences, Inc. Fred Alger Mngmt holds 590,232 shares or 0.23% of its portfolio.

Stephen Dubois increased its stake in Gilead Sciences Inc. State Bank Hapoalim Bm reported 36,629 shares stake. Pioneer Investment Mgmt Inc stated it has 0.69% in Gilead Sciences, Inc.

The S&P 500 closed up 4 points, and the Dow Jones finished up 30 points, but the tech-heavy Nasdaq Composite lost ground, losing six points at 6,266.

MaxPoint Interactive Inc (NASDAQ: MXPT) shares shot up 149 percent to $13.67 after the company agreed to be acquired by Valassis for $13.86 per share in cash.

Analysts have a mean recommendation of 2.50 on this stock (A rating of less than 2 means buy, "hold" within the 3 range, "sell" within the 4 range, and "strong sell" within the 5 range). Unicredit S.p.A had 8 analyst reports since August 6, 2015 according to SRatingsIntel.

Gilead Sciences is a biopharmaceutical company that discovers, develops and commercializes innovative therapeutics in areas of unmet medical need. (NASDAQ:GILD) has "Buy" rating given on Wednesday, October 5 by Jefferies. HSBC maintained Morgan Advanced Materials PLC (LON:MGAM) on Tuesday, August 16 with "Buy" rating. DOUMANI ROY sold $1.27M worth of Kite Pharma Inc (NASDAQ:KITE) on Wednesday, June 7.

Like this: